Literature DB >> 16822090

Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia.

Stefan Leucht1, Stephan Heres.   

Abstract

Partial adherence and nonadherence to medication continue to be problems in the treatment of patients with schizophrenia. Nonadherence to medication has a negative impact on the course of illness for these patients as is shown by data on relapse, rehospitalization, time to remission, and attempted suicide. Several factors that contribute to poor adherence have been identified and need to be taken into account when attempting to address the problem of nonadherence. These risk factors relate to the patient, his or her illness and social situation, and the physician. Among the measures that have the potential to improve adherence to medication are psychosocial interventions, psychoeducation in the form of professional, peer-to-peer or family-to-family interventions, and shared decision making.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16822090

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  55 in total

Review 1.  Medication adherence in schizophrenia.

Authors:  Francisco Javier Acosta; José Luis Hernández; José Pereira; Judit Herrera; Carlos J Rodríguez
Journal:  World J Psychiatry       Date:  2012-10-22

2.  The revolving door phenomenon in psychiatry: comparing low-frequency and high-frequency users of psychiatric inpatient services in a developing country.

Authors:  Ulla A Botha; Liezl Koen; John A Joska; John S Parker; Neil Horn; Linda M Hering; Piet P Oosthuizen
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-06-18       Impact factor: 4.328

Review 3.  The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Authors:  Sofia Brissos; Miguel Ruiz Veguilla; David Taylor; Vicent Balanzá-Martinez
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

4.  Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).

Authors:  Rosario de Arce Cordón; Evelin Eding; Joao Marques-Teixeira; Vihra Milanova; Elmars Rancans; Andreas Schreiner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-08-02       Impact factor: 5.270

5.  Long-Acting Injectable (LAI) Aripiprazole Formulations in the Treatment of Schizophrenia and Bipolar Disorder: a Systematic Review.

Authors:  Chiara Rapinesi; Georgios D Kotzalidis; Lorenzo Mazzarini; Roberto Brugnoli; Stefano Ferracuti; Sergio De Filippis; Ilaria Cuomo; Gloria Giordano; Antonio Del Casale; Gloria Angeletti; Gabriele Sani; Paolo Girardi
Journal:  Clin Drug Investig       Date:  2019-08       Impact factor: 2.859

6.  Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial.

Authors:  Wolfgang Gaebel; Andreas Schreiner; Paul Bergmans; Rosario de Arce; Frédéric Rouillon; Joachim Cordes; Lars Eriksson; Enrico Smeraldi
Journal:  Neuropsychopharmacology       Date:  2010-08-04       Impact factor: 7.853

7.  Schizophrenia--time to commit to policy change.

Authors:  W Wolfgang Fleischhacker; Celso Arango; Paul Arteel; Thomas R E Barnes; William Carpenter; Ken Duckworth; Silvana Galderisi; Lisa Halpern; Martin Knapp; Stephen R Marder; Mary Moller; Norman Sartorius; Peter Woodruff
Journal:  Schizophr Bull       Date:  2014-04       Impact factor: 9.306

8.  Bioequivalence of clozapine orally disintegrating 100-mg tablets compared with clozapine solid oral 100-mg tablets after multiple doses in patients with schizophrenia.

Authors:  Gil Golden; Gilbert Honigfeld
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

9.  Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia.

Authors:  Rosaria Di Lorenzo; Alice Brogli
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

Review 10.  Improving treatment adherence in your patients with schizophrenia: the STAY initiative.

Authors:  Fernando Cañas; Koksal Alptekin; Jean Michel Azorin; Vincent Dubois; Robin Emsley; Antonio G García; Philip Gorwood; Peter M Haddad; Dieter Naber; José M Olivares; Georgios Papageorgiou; Miquel Roca
Journal:  Clin Drug Investig       Date:  2013-02       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.